Cost‐effectiveness of new antiviral regimens for treatment‐naïve U.S. veterans with hepatitis C
暂无分享,去创建一个
Kenneth J. Smith | Shari S. Rogal | M. Fine | L. Myaskovsky | A. Tsung | C. Bryce | C. Good | V. Rustgi | Larissa Myaskovsky | Allan Tsung | Alexis P. Chidi | Shari Rogal | Cindy L. Bryce | Michael J. Fine | Chester B. Good | Vinod K. Rustgi | Kenneth J. Smith | A. Chidi
[1] Eoin Coakley,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.
[2] Brian L. Pearlman,et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.
[3] R. Cheung,et al. Implications of rapid virological response in hepatitis C therapy in the US veteran population , 2012, Alimentary pharmacology & therapeutics.
[4] D. Harnois,et al. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .
[5] Thomas Berg,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.
[6] P. Terasaki,et al. Liver transplantation in the United States. , 2005, Clinical transplants.
[7] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[8] Peter J. Richardson,et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. , 2012, Journal of hepatology.
[9] William M. Lee,et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C , 2011, Hepatology.
[10] S. Pol,et al. FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.
[11] A. Butt,et al. Effect of hepatitis C virus and its treatment on survival , 2009, Hepatology.
[12] J. R. Scotti,et al. Available From , 1973 .
[13] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[14] L. Henry,et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. , 2014, Journal of hepatology.
[15] D. Thompson,et al. The burden of illness associated with hepatocellular carcinoma in the United States. , 2009, Journal of hepatology.
[16] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[17] T. Brennan,et al. Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus , 2015, Annals of Internal Medicine.
[18] B. Luxon,et al. Limited success of HCV antiviral therapy in United States veterans , 2002, American Journal of Gastroenterology.
[19] S. Holmberg,et al. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs , 2015, Annals of Internal Medicine.
[20] B. McNeil,et al. Probabilistic Sensitivity Analysis Using Monte Carlo Simulation , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.
[21] S. Saab,et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[22] P. Thuras,et al. All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C , 2014, Digestive Diseases and Sciences.
[23] G. Davis,et al. Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[24] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[25] Y. Yazdanpanah,et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). , 2014, Journal of hepatology.
[26] Va Puget. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers , 2005 .
[27] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[28] A. Borkowski,et al. Hepatitis C genotype analysis: results in a large veteran population with review of the implications for clinical practice. , 2012, Annals of clinical and laboratory science.
[29] Nathaniel D. Bastian,et al. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US , 2015, BMC Gastroenterology.
[30] R. Wolfe,et al. Trends in Organ Donation and Transplantation in the United States, 1996–2005 , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] Robert Herring,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.
[32] John McNally,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.
[33] R. Schinazi,et al. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals , 2014, Hepatology.
[34] P. Heagerty,et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers , 2005, Hepatology.
[35] E. Schiff,et al. Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[36] Peter G. Stock,et al. OPTN/SRTR 2011 Annual Data Report: Liver , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[37] M. Stepanova,et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). , 2014, Journal of hepatology.
[38] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[39] S. Asch,et al. Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration , 2013 .
[40] M. Golden,et al. Cost-effectiveness and population outcomes of general population screening for hepatitis C. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] T. Hassanein,et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial , 2013, The Lancet.
[42] J. Chhatwal,et al. The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions , 2014, Annals of Internal Medicine.
[43] M. Stepanova,et al. Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens , 2014, Hepatology.
[44] J. Kaldor,et al. Estimation of Utilities for Chronic Hepatitis C from SF-36 Scores , 2005, The American Journal of Gastroenterology.
[45] G. Dore,et al. Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression , 2008, Hepatology.
[46] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[47] Aijaz Ahmed,et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.
[48] R. Wolfe,et al. Trends in Organ Donation and Transplantation in the United States, 1999–2008 , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[49] R. Marinho,et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.
[50] R. Solá,et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. , 2004, Journal of hepatology.
[51] A. Bhalla,et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.
[52] S. El-Kamary,et al. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] G. Foster,et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection , 2010, Alimentary pharmacology & therapeutics.
[54] J. Hanmer. Predicting an SF-6D preference-based score using MCS and PCS scores from the SF-12 or SF-36. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[55] R. Schinazi,et al. All‐oral, interferon‐free treatment for chronic hepatitis C: cost‐effectiveness analyses , 2013, Journal of viral hepatitis.
[56] M. Roberts,et al. What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? , 2008, Medical care.
[57] J J Fung,et al. Liver Transplantation in the United States, 1999–2008 , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.